arrow
M

Mitchell C. Posner

university of chicago
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
2022-08-050
PRE
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels
2022-01-055
OAAI
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
2021-02-0248
OA
4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis
2020-08-2627
OAAI
Medically Necessary, Time-Sensitive Procedures: Scoring System to Ethically and Efficiently Manage Resource Scarcity and Provider Risk During the COVID-19 Pandemic

医疗上必要的、时间敏感的程序: 在新型冠状病毒肺炎大流行期间道德和有效地管理资源稀缺和提供者风险的评分系统

2020-08-01247
OAAI
Perioperative Gemcitabine plus Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial
2019-08-1519
OAAI
Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial

ACOSOG Z6051随机对照试验的随访结果比较 ⅱ ~ ⅲ 期直肠癌腹腔镜切除术与开腹切除术的无病生存和局部复发

2019-04-01302
OAAI
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis (vol 9, 1793, 2018)
2018-11-133
OAAI